North Carolina
Prescription drug spending and prescribing in North Carolina, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $10.2B for prescriptions written in North Carolina, the 7th most of 52 states and territories, and 4.2% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $10.2B
- Medicaid drugs, 2025: $4.7B
- Opioid share of claims: 4.2%
- Life-science raises, 2 years: $900M
Opioid share of Part D claims, 2024
North Carolina outlined; every state in quartiles. Click a state to compare.
- Up to 3.2%
- 3.2% to 3.7%
- 3.7% to 4.3%
- Over 4.3%
| Share of Part D claims | North Carolina | United States | Difference |
|---|---|---|---|
| Opioids | 4.2% | 3.5% | +18% |
| Antibiotics | 4.3% | 4.4% | −3% |
| Antipsychotics | 1.5% | 1.7% | −12% |
| Drug | Against national rate | Claims |
|---|---|---|
| Oxycodone myristate | 3.0× | 39,294 |
| Dofetilide | 2.0× | 23,309 |
| Molnupiravir | 1.9× | 14,144 |
| Promethazine HCl | 1.9× | 87,114 |
| Rabeprazole sodium | 1.8× | 18,377 |
| Telmisartan/hydrochlorothiazid | 1.7× | 15,454 |
| Buprenorphine | 1.7× | 30,734 |
| Telmisartan | 1.7× | 77,557 |
| Buprenorphine HCl | 1.7× | 34,476 |
| Suvorexant | 1.6× | 17,410 |
- Kriya Therapeutics, Inc.$321M · Biotech · Aug 15, 2025
- Atsena Therapeutics, Inc.$90M · Biotech · Apr 11, 2025
- RESTOR3D, Inc.$85M · Other health care · Aug 22, 2025
- Pelthos Therapeutics Inc.$58M · Pharma · Nov 16, 2026
- Belhaven Biopharma Inc.$32M · Pharma · Oct 15, 2025
- RESTOR3D, Inc.$28M · Other health care · Jan 30, 2025
- Ramona Optics, Inc.$26M · Biotech · Mar 12, 2026
- Xilis, Inc.$19M · Biotech · Apr 25, 2025
- Pelthos Therapeutics Inc.$18M · Pharma · Nov 19, 2025
- Hoofprint Biome, Inc.$15M · Biotech · May 27, 2025
- Plaintiff States and FTC v. CVET TOPCO, L.P. et al.2026 · Pending
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- FTC et al. v. Vyera Pharmaceuticals, No. 1:20-cv-00706 (S.D.N.Y. Apr. 19, 2020)2020 · Final judgment
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Florida et al. v. Abbott Laboratories et al., No. 1:08-cv-00155-SLR (D.Del. 2007)2007 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG